Clinical Trial Update: 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating 18F-AraG PET/CT as a non-invasive imaging biomarker to assess chemoradiation response in esophageal cancer; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• 18F-AraG

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Esophageal Cancer | Phase 1 | Status: RECRUITING